Incidence & Predictors of Mechanical Abnormalities of QuickSite® and QuickFlex® Left Ventricular Pacing Leads
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
On April 2, 2012 the manufacturer of the Quicksite® and Quickflex® leads, St. Jude Medical, released a voluntary medical device advisory regarding these leads' potential for problems with the silicone insulation covering one end of the lead, where it meets another section of the lead which is coated with a different insulating material (polyurethane). There has been a voluntary suspension of sales of these leads.
There are approximately 179,000 of the above leads implanted worldwide with an estimated 101,000 leads currently in service (59,000 in US). There have been 39 confirmed cases of the conductor portion of the lead becoming exposed from the silicone insulation (externalization), and the rate of occurrence of this type of problem is conservatively estimated at less than one percent. However, a review done by St. Jude Medical of returned Quicksite® and Quickflex® leads and available X-ray and fluoroscopic (x-ray movie) images of patients with these leads (from 1,219 patients) revealed a higher rate of 3-4%. It is presumed that there are patients whose leads have not yet been affected by this problem, but whose leads may show signs of structural changes on x-ray or fluoroscopy. This study seeks to determine what structural changes may be occurring in these leads, what signs might predict these changes, and what impact these changes may have on the lead and its performance.
| Condition | Intervention |
|---|---|
|
Left Ventricular Pacing Leads |
Device: Quicksite Device: Quickflex |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Incidence & Predictors of Mechanical Abnormalities of QuickSite® and QuickFlex® Left Ventricular Pacing Leads: Impact on Electrophysiological Profile |
- Evaluate the mechanical/structural abnormalities in implanted St Jude Medical QuickSite® and QuickFlex® left ventricular (LV) pacing leads [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 190 |
| Study Start Date: | July 2012 |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Quicksite and Quickflex
Patients who have received the leads affected by the medical product advisory
|
Device: Quicksite
St. Jude Medical produced lead called Quicksite
Device: Quickflex
St. Jude Medical produced lead called Quickflex
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patients that received either Quicksite or Quickflex leads at the University of Kansas Hospital
Inclusion Criteria:
- Patient that received Quicksite or Quickflex lead at the University of Kansas Hospital
Exclusion Criteria:
- Not willing to consent to data collection
Contacts and Locations| United States, Kansas | |
| University of Kansas Medical Center | |
| Kansas City, Kansas, United States, 66160 | |
| Principal Investigator: | Dhanunjaya Lakkireddy, MD | University of Kansas |
More Information
No publications provided
| Responsible Party: | Dhanunjaya Lakkireddy, MD, FACC, Associate Professor, University of Kansas Medical Center Research Institute |
| ClinicalTrials.gov Identifier: | NCT01636804 History of Changes |
| Other Study ID Numbers: | 13211 |
| Study First Received: | July 5, 2012 |
| Last Updated: | January 22, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Kansas:
|
Quicksite Quickflex St. Jude Medical |
Additional relevant MeSH terms:
|
Congenital Abnormalities Menthol Antipruritics |
Dermatologic Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 21, 2013